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HAS PROPRANOLOL RENDERED SCLEROTHERAPY OBSOLETE
FOR POOR RISK ALCOHOLIC CIRRHOTIC PATIENTS?
ABSTRACT
Ink, 0., Martin, T., Poynard, T., Reville, M., Anciaux, M.-L, Lenoir, C., Marill, J.-L.,
Labadie, H., Masliah, C., Perrin, D., Chaput, J.-C., Vetter, D., Eugene, C., Lebodic, L.,
Licht, H. and Etienne, J.-P. (1992) Does elective sclerotherapy improve the efficacy of
long-term propranolol jbr prevention of recurrent bleeding in patients with severe
cirrhosis? A prospective multicenter, randomized trial. Hepatology; 16:912-919
We conducted a prospective, multicenter, randomized trial to compare the efficacy of
sclerotherapy plus propranolol with that of propranoloi alone in the prevention of
recurrent gastroesophageal bleeding in severely cirrhotic patients. For 2 yr (1987 to 1988)
131 patients (96% ofwhom were alcoholic) with Child-Pugh class B or C cirrhosis (56%
were class B and 44% were class C) were randomly assigned to one of our two treatment
groups after cessation of variceal bleeding, without hernostatic sclerosis, and were
observed for at least 2 yr. Treatment observance was good in 89% of cases; alcohol
withdrawal was observed in 62% of cases. Sclerotherapy was performed weekly with 1%
polidocanol, and variceal obliteration was obtained in 83% ofcases, in a mean number of
four sessions. "lhe cumulative percentages (expressed as mean __+ S.D.) of recurrent
bleeding at 2 yr were 42% ___
6% for propranolol plus sclerotherapy and 59% +_ 6% for
propranolol alone (a nonsignificant difference). Twenty-eight patients from the prop-
ranolol group but only 12 patients from the propranoloi-plus-sclerotherapy group had
recurrent bleeding from esophageal variceal rupture (p < 0.01). The total number of blood
units per patient with recurrent bleeding was slightly but not significantly more important
in the propranolol group (8 __+ 7) than in the propranoloi-plus-sclerotherapy group (5 ___
5;
p--0.09). There were no statistical differences in the cumulative survival rate at 2 yr
(propranolol plus sclerotherapy, 74% __+ 6% and propranolol alone, 64% __+ 6%) or in the
number of patients who died of repeat bleeding (propranolol plus sclerotherapy,
13% __+ 4% and propranolol alone, 17% + 5%). Among the surviving patients, cirrhosisHPB INTERNATIONAL 75
improved during the follow-up; Chiid-Pugh classification was the following at I mo: 35%
for class A, 50% for classB and 15% for classC and the following at 2 yr:58% for class A,
38% for class B and 4% for class C. In conclusion, elective sclerotherapy does not
significantly decrease the rate of recurrent bleeding or death inseverely cirrhotic patients
who are treated with propranoloi and who mainly abstain from drinking alcohol.
(HEPATOLOGY 1992; 16:912--919.)
KEY WORDS: Portal hypertension; bleeding oesophageal varices; sclerotherapy;
propranolol; alcoholic cirrhosis.
PAPER DISCUSSION
This is the first report ofa prospective randomized trial
comparing sclerotherapy plus propranolol and prop-
ranolol alone for prevention of recurrent bleeding in
patients with severe alcoholic cirrhosis. They found no
beneficial effects ofelective sclerotherapy regarding the
efficacy oflong-term propranolol; the only positive find-
ing was a decreased rate of recurrent episodes of bleed-
ing from oesophageal varices after sclerotherapy 1.
Lebrec et al.2’3 seemed to have been the first to use
propranolol for prevention of recurrent bleeding from
oesophageal varices; they reported a high rate ofbleed-
ing (36%)during a 2 year period. The rates ofrecurrent
bleeding and mortality are comparable with those
reported by other workers4’5. The mortality may part-
ly be due to liver failure in patients with Child’s C liver
functions, because ofa reduction in portal pressure; the
objective of propranolol administration. The de-
creased rate of variceal bleeding may counter-balance
any deterioration in the liver function by decreased
portal flow.
Two other forms of prospective randomized trials
have been carried out for.the evaluation ofpropranolol
and sclerotherapy; propranolol vs. sclerotherapy,
and sclerotherapy plus propranolol vs. sclerotherapy.
Propranolol seems comparable with sclerotherapy for
prevention of variceal bleeding5’6. There are trials7’8
suggesting that propranolol can reduce recurrent
gastro-oesophageal bleeding in cirrhotic patients
during the course of elective sclerotherapy. In the
present trial in which propranolol alone or prop-
ranolol plus sclerotherapy was compared, there were
no obvious benefits of sclerotherapy in the course of
this therapy.
One possible explanation for the failure of any en-
hancing effect of sclerotherapy in patients treated with
propranolol is the technique used for sclerotherapy, as
well as the entry criteria and follow-up. The oral
administration of propranolol presents no problem
and intolerance by the patients is the only untoward
event. On the other hand, effective sclerotherapy re-
quires much experience to obtain good results, other-
wise, there will be a higher rate of recurrent bleeding
from the varices. There are variants of sclerotherapy
technique with some showing higher bleeding rates
and a high mortality5’9, albeit lower than those in the
study in question 1. The type of sclerosant, injection
intervals, rigid follow-up and endpoint o are vital fac-
tors to achieve the intended outcome. The high rate of
bleeding from varices and the ensuing ulceration in the
early stage of sclerotherapy may explain the high mor-
tality rate due to bleeding and liver failure in their
study 1. Bleeding was the result of an incomplete
thrombosis not only in the main variceal channels but
also in the surrounding small channels. There was
a high rate of bleeding episode before variceal obliter-
ation in the sclerotherapy group (56%, 14 out of 25);
much higher than in other series5’11. At 2 years, there
was a high rate of recurrent bleeding (42%) which can
be attributed to the low rate of variceal eradication
(82%), in the present trial. With appropriate tech-
niques, variceal bleeding can be prevented, as there are
no varices to bleed if all varices are eradicated. Using
an improved sclerotherapy technique a sufficient vol-
ume of 5% ethanolamine oleate (a more potent scler-
osant than 1% polidocanol) is injected and the ensuing
denuding of the distal oesophageal mucosa prevents
recurrence of varices, and the rate ofbleeding is greatly
diminished and the prognosis is much improved1.
The technique used for sclerotherapy should be given
much more focus when evaluating clinical data, be-
cause multicenter trials always raise the problem re-
garding uniformity of technique; in some institutions
the bleeding rate may be much higher than in other
clinics.
Ink et al. clearly showed that. the occurrence of
repeat bleeding was a major prognostic factor for
prediction of survival during the study period; 50% of
the patients had recurrent bleeding episodes (30 of 60)76 HPB INTERNATIONAL
and only 14% ofthe patients had no recurrent bleeding
episodes (10 of 71).
Patients with oesophageal varices were included in
the present trial, and judged as variceal bleeding, be-
cause there was no other potential source of bleeding;
one third of such patients were included in this trial, as
cases of variceal bleeding. Bleeding may occur because
of gastritis which is very difficult to identify more than
12 hours later. It may be a reasonable finding that
elective sclerotherapy did not reduce the rate of upper
gastrointestinal bleeding in patients given propranolol.
It may be that elective sclerotherapy showed no benefit
for prevention ofboth esophago-gastric variceal bleed-
ing and non-variceal gastric bleeding, because sclero-
therapy may elevate portal pressure following the
blockage of large collaterals of portal system and
bleeding from the stomach, in the presence ofincreased
portal hypertension may occur2.
In the present trial, alcohol withdrawal was ob-
served only in 62% ofthe patients, although the numb-
er was not given separately for the two groups. There
was a high rate of "lost to follow up," perhaps due to
alcohol abuse. Abstinence from alcohol is a key factor
in the follow-up of patients and in achieving improved
clinical results after sclerotherapy. Because additional
sessions of sclerotherapy are essential; the number of
patients with recurrence of varices, and these requiring
additional treatment should be documented during the
follow-up period.
Indeed there was a significant difference in the rates
of recurrent bleeding due to variceal rupture between
the two groups; 28 of the 65 patients in the scler-
otherapy plus propranolol vs. 12 of 66 patients in the
propranolol alone group. The greater the expertise
with sclerotherapy the smaller the number of bleed-
ing episodes will become with a greater decrease in
mortality.
It is reasonable that elective sclerotherapy did not
produce a benefit in the management of patients on
propranolol therapy, unless their varices were at high
risk of bleeding; this should be confirmed endoscopi-
cally. Even in patients with small non-risky varices,
sclerotherapy may induce oesophageal bleeding by
creating an ulcer at the injection sites, or by precipitat-
ing non-variceal bleeding, such as bleeding from gas-
tritis due to elevation in portal pressure. The current
series demonstrates that elective sclerotherapy can
benefit patients in the prevention of recurrent short
and medium term variceal bleeding, despite a high rate
of postinjection bleeding.
Sclerotherapy is useful for controlling acute variceal
bleeding, not only because this procedure can be per-
formed along with emergency endoscopy for a diag-
nosis but also because the control rate is high. Long
term results after sclerotherapy will improve with ap-
propriate techniques.
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